| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Biofarm S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | RON0.80 |
| 52 Week High | RON0.84 |
| 52 Week Low | RON0.58 |
| Beta | 0.34 |
| 1 Month Change | 3.90% |
| 3 Month Change | 8.40% |
| 1 Year Change | 34.23% |
| 3 Year Change | 95.12% |
| 5 Year Change | 137.39% |
| Change since IPO | 106.84% |
Recent News & Updates
Recent updates
Is Biofarm S.A.'s (BVB:BIO) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Mar 18
Is There More To The Story Than Biofarm's (BVB:BIO) Earnings Growth?
Feb 18
Shareholders Of Biofarm (BVB:BIO) Must Be Happy With Their 140% Total Return
Jan 23A Look At The Intrinsic Value Of Biofarm S.A. (BVB:BIO)
Dec 25Could The Biofarm S.A. (BVB:BIO) Ownership Structure Tell Us Something Useful?
Dec 03Shareholder Returns
| BIO | RO Pharmaceuticals | RO Market | |
|---|---|---|---|
| 7D | -2.2% | -1.1% | 0.7% |
| 1Y | 34.2% | 3.5% | 10.7% |
Return vs Industry: BIO exceeded the RO Pharmaceuticals industry which returned 2.9% over the past year.
Return vs Market: BIO exceeded the RO Market which returned 10.7% over the past year.
Price Volatility
| BIO volatility | |
|---|---|
| BIO Average Weekly Movement | 2.3% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 3.0% |
| 10% most volatile stocks in RO Market | 7.1% |
| 10% least volatile stocks in RO Market | 2.3% |
Stable Share Price: BIO is less volatile than 75% of RO stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: BIO's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1921 | 402 | Vicol Constantin | https://www.biofarm.ro |
Biofarm S.A. manufactures and sells medicines in Romania. The company offers a portfolio of products covering therapeutic areas, such as antiallergics, cardiovascular and circulatory, analgesics and antipyretics, dermatological, digestive and metabolic, endocrine, genitourinary, multivitamins, ophthalmologic, musculoskeletal, respiratory and ENT, and neurological. It provides prescription and non-prescription medicines, food supplements, medical devices, cosmetics, and other products.
Biofarm S.A. Fundamentals Summary
| BIO fundamental statistics | |
|---|---|
| Market Cap | RON788.29m |
| Earnings (TTM) | RON75.13m |
| Revenue (TTM) | RON297.14m |
10.5x
P/E Ratio2.7x
P/S RatioIs BIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIO income statement (TTM) | |
|---|---|
| Revenue | RON297.14m |
| Cost of Revenue | RON53.94m |
| Gross Profit | RON243.21m |
| Other Expenses | RON168.07m |
| Earnings | RON75.13m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.076 |
| Gross Margin | 81.85% |
| Net Profit Margin | 25.29% |
| Debt/Equity Ratio | 0% |
How did BIO perform over the long term?
See historical performance and comparison